Edition:
United Kingdom

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,128JPY
13 Sep 2019
Change (% chg)

¥20 (+1.81%)
Prev Close
¥1,108
Open
¥1,111
Day's High
¥1,131
Day's Low
¥1,103
Volume
141,400
Avg. Vol
74,096
52-wk High
¥1,786
52-wk Low
¥1,073

Latest Key Developments (Source: Significant Developments)

Seikagaku says clinical trial for SI-449
Monday, 21 May 2018 

May 21 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a clinical trial (pilot study) in Japan for SI-449, an adhesion barrier for use in surgery .  Full Article

Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan
Friday, 23 Mar 2018 

March 23(Reuters) - Seikagaku Corp <4548.T>:Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation.  Full Article

Ribomic signs collaborative research contract with SEIKAGAKU
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.  Full Article

Photo

Blue-blooded crabs at heart of pharma dispute on drug testing

ZURICH If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.